Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL
Key insights from lung cancer research at ASCO 2025
POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma
Understanding Ghana's FDA and pharmacovigilance regulations
ASCO 2025: Importance of early testing in metastatic prostate cancer
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer
New MOAs in prostate cancer treatment - what’s next?
Making immune check point inhibitors for lung cancer cost-effective in LMICs
Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery
Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer